PD-L1 testing is one of several factors that influence therapy selection in cancer treatment.\textsuperscript{1,2} AstraZeneca and MedImmune developed a fully-validated immunohistochemistry (IHC) test that determines levels of PD-L1 expression on both tumour cells (TC+) and infiltrating immune cells (IC+).\textsuperscript{1}

We are continuing our leading research in PD-L1 testing concordance, working with trained pathologists to evaluate multiple assays to work towards harmonization.\textsuperscript{1} This will help the scientific community better understand PD-L1 expression and ultimately help bring IO therapies to more patients.

PD-L1 expression is not binary. Until now, patients have been classified as either positive or negative but PD-L1 expression is better understood along a continuum.\textsuperscript{5,7} Depending on the potential therapy or indication, the appropriate cut-off point for classifying a patient may differ.\textsuperscript{1} 